Semprus BioSciences

Semprus BioSciences, headquartered in Cambridge, Massachusetts, is a venture-backed biomedical company with a dual mission: to provide complication-free medical devices designed to preserve patients' long-term health and quality-of-life and to contribute to health care cost efficiencies. Our innovative, multi-faceted approach to durable surface modifications signifies a breakthrough in medical device technology. Our current focus is to enable the first permanently dual-functional (anti-colonization and anti-thrombogenic) vascular access catheter with a single surface modification. Founded out of the Massachusetts Institute of Technology's Langer Lab, the company has developed the next-generation biofunctional surface platform – which is focused on achieving clinical benefits that far exceed current market offerings containing silver, heparin, and antibiotic coatings. Through covalent chemical bonding of our Semprus Surfaces™, a permanent non-leaching biomaterial modification to the device surface, our technology is expected to vastly improve patient outcomes by preventing serious medical complications, such as infection, blood clots, improper healing, and cell overgrowth. We have assembled a world class product development team – scientists, industry executives and clinical experts – who specialize in reducing such complications at the confluence of the human body and implantable devices.

• Employees 3
• Founded 2006
• Annual Revenue $3000000
• Total Funding $8000000